Studies in molecular modeling, in vitro CDK2 inhibition and antimetastatic activity of some synthetic flavones

被引:6
|
作者
Wagal, Ojas S. [1 ]
Joshi, Akshada J. [1 ]
Joshi, Urmila J. [1 ]
Bhojwani, Heena R. [1 ]
Begwani, Khushboo, V [1 ]
Dawne, Harshank A. [1 ]
Gude, Rajiv P. [2 ]
Sathaye, Sadhana S. [3 ]
Kanchan, Divya M. [3 ]
机构
[1] Principal KM Kundnani Coll Pharm, Dept Pharmaceut Chem, Mumbai 400005, Maharashtra, India
[2] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Canc Res Inst, Gude Lab, Mumbai 410210, Maharashtra, India
[3] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Mumbai 400019, Maharashtra, India
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2021年 / 26卷 / 04期
关键词
Flavones; Metastasis; Melanoma; CDK2; Molecular Docking; MD Simulation; CANCER-CELLS; LUTEOLIN; KINASE; DOCKING; GROWTH; PENTOXIFYLLINE; APOPTOSIS; ARREST; GLIDE; CYCLE;
D O I
10.2741/4911
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Naturally occurring flavonoids have been shown to possess anticancer activity. We have previously shown that certain synthetic flavonoids also exert significant antiproliferative potential in MOLT-4, MCF-7, and HepG2 cell lines. To this end, we evaluated eight synthetic flavones for their CDK2 binding by molecular docking. Most flavones showed interaction with Leu 83. Based on docking and antiproliferative activity, we chose 3'-nitroflavone and 3', 5'-dimethoxyflavone for the molecular dynamics (MD) simulation and CDK2 inhibition studies. MD simulation studies confirmed interactions with CDK2 (as observed in docking). Furthermore, the inhibitory activities of CDK2/cyclin A2 enzyme for 3'-nitroflavone and 3', 5'-dimethoxyflavone were found to be 6.17 and 7.19 mu M, respectively. 3'-nitroflavone and 3', 5'-dimethoxyflavone displayed moderate activity in colony formation assay, wound-scratch assay, and Leighton tube studies. Based on these data, the synthesized flavones might have clinical potential as potential inhibitors of CDK2.
引用
收藏
页码:664 / 681
页数:18
相关论文
共 50 条
  • [1] Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies
    Joshi, Akshada
    Bhojwani, Heena
    Wagal, Ojas
    Begwani, Khushboo
    Joshi, Urmila
    Sathaye, Sadhana
    Kanchan, Divya
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (03) : 328 - 343
  • [2] Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors
    Zhang, Gaomin
    Ren, Yujie
    MOLECULES, 2018, 23 (11):
  • [3] Synthesis of Some Novel Benzimidazole Derivatives as Anticancer Agent and Evaluation for CDK2 Inhibition Activity
    Abd El-Hameed, Rania Helmy
    Fatahala, Samar Said
    Sayed, Amira Ibrahim
    MEDICINAL CHEMISTRY, 2022, 18 (02) : 238 - 248
  • [4] Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine
    Garcia, Tamara B.
    Fosmire, Susan P.
    Porter, Christopher C.
    LEUKEMIA RESEARCH, 2018, 64 : 30 - 33
  • [5] Synthesis and in vitro anticancer activity of some 2-oxindoline derivatives as potential CDK2 inhibitors
    Alshaye, Najla A.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (24) : 15009 - 15022
  • [6] Molecular modeling and in vitro antiproliferative activity studies of some imidazole and isoxazole derivatives
    Muhammed, Muhammed Tilahun
    Mustafa, E. R.
    Akkoc, Senem
    JOURNAL OF MOLECULAR STRUCTURE, 2023, 1282
  • [7] Some indazoles reduced the activity of human serum paraoxonase 1, an antioxidant enzyme: in vitro inhibition and molecular modeling studies
    Alim, Zuhal
    Kilic, Deryanur
    Demir, Yeliz
    ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 2019, 125 (05) : 387 - 395
  • [8] Identification of New Inhibitors of the Kinase Activity of CDK2 and CDK9 by Molecular Modeling and High-Efficiency Screening
    Andrianov, G., V
    Serebriiskii, I. G.
    UCHENYE ZAPISKI KAZANSKOGO UNIVERSITETA-SERIYA ESTESTVENNYE NAUKI, 2021, 163 (04): : 543 - 556
  • [9] HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
    Juengel, Eva
    Nowaz, Snigdha
    Makarevi, Jasmina
    Natsheh, Iyad
    Werner, Isabella
    Nelson, Karen
    Reiter, Michael
    Tsaur, Igor
    Mani, Jens
    Harder, Sebastian
    Bartsch, Georg
    Haferkamp, Axel
    Blaheta, Roman A.
    MOLECULAR CANCER, 2014, 13
  • [10] Imidazo[1,2,4]triazolone and fused imidazo[1,2,4]triazolone derivatives: Synthesis, in vitro anticancer screening, CDK2 inhibitory activity, and molecular modeling studies
    El Rabeeb, Shaimaa, I
    El Deeb, Moshira A.
    Sarg, Marwa T.
    Hassan, Aisha Y.
    JOURNAL OF HETEROCYCLIC CHEMISTRY, 2022, 59 (12) : 2207 - 2224